Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS)
🎯 Key Takeaways
- Aarey Drugs & Pharmaceuticals Ltd appears to be in a consolidation and stabilization phase following a period of volatility, with management focusing on operational discipline and compliance rather than aggressive growth. The company operates in a capital-intensive segment with low margins and modest profitability, as reflected in its single-digit ROE and ROCE.
- Revenue declined 76.4% QoQ to ₹45 in Q1FY27.
- ⚠️ Persistent low margins and volatility in revenue and profitability raise concerns about operational resilience, especially with no clear demand recove
- Market Cap
- ₹281
- P/E Ratio
- 67.5
- P/B Ratio
- 1.87
- ROE
- 2.8%
- ROCE
- 4.9%
- Debt/Equity
- 0.33
- Promoter
- 37.7%
📖 The Story
Aarey Drugs & Pharmaceuticals Ltd appears to be in a consolidation and stabilization phase following a period of volatility, with management focusing on operational discipline and compliance rather than aggressive growth. The company operates in a capital-intensive segment with low margins and modest profitability, as reflected in its single-digit ROE and ROCE. Recent financial trends show erratic revenue and profitability, but management emphasizes adherence to regulatory norms and fund utilization transparency.
📰 What's Happening
Management has prioritized regulatory compliance and insider trading protocols, repeatedly highlighting trading window closures and openings tied to quarterly results announcements. The board approved unaudited Q1 FY26 results on August 14, 2026, reporting revenue of ₹45 crore, profit before tax of ₹0 crore, and EPS of ₹0.36, with no material misstatements identified. Earlier, on May 30, 2026, the board finalized audited FY26 results, confirming an unmodified audit opinion and acknowledging deviations in fund utilization related to convertible warrants issued previously. These actions underscore a cautious, compliance-driven approach to governance, with no major strategic shifts or new investments disclosed recently.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 102 | 84 | 96 | 189 | 45 |
| Operating Profit | 1 | 2 | -2 | 3 | 0 |
| OPM % | 1.2% | 2.3% | -2.4% | 1.8% | 1.1% |
| Net Profit | 1 | 1 | 1 | 2 | 1 |
| EPS | ₹0.48 | ₹0.36 | ₹0.20 | ₹0.55 | ₹0.36 |
The company’s quarterly performance reveals significant volatility, with revenue peaking at ₹189 crore in Q4 FY26 before collapsing to ₹45 crore in Q1 FY27, accompanied by a sharp decline in operating profit from ₹3 crore to ₹0 crore and a drop in EPS from ₹0.55 to ₹0.36. This downturn appears to be seasonal or demand-related, but management has not attributed it to structural issues, instead framing it within normal operational cycles. The consistent EPS of ₹0.36 in Q1 FY27, despite lower revenue, suggests cost control or one-time factors at play, though gross profitability remains thin with OPM compressing to 1.1%.
🔮 Management Outlook & What's Next
Management has not provided forward-looking guidance on revenue, margins, or capital allocation in the reviewed filings, focusing instead on procedural compliance and audit outcomes. The repeated emphasis on SEBI insider trading norms and audit committee validation indicates a risk-averse communication style, with no strategic roadmap or growth targets disclosed. The absence of commentary on demand trends, pricing, or pipeline suggests limited visibility into near-term performance drivers.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2025 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 28 | 28 | 28 | 28 |
| Reserves | 105 | 108 | 122 | 117 |
| Borrowings | 35 | 39 | 50 | 51 |
| Total Liabilities | 291 | 275 | 297 | 294 |
| Fixed Assets | 16 | 13 | 26 | 25 |
| Investments | 2 | 1 | 2 | 2 |
| Total Assets | 291 | 275 | 297 | 294 |
The balance sheet shows stable equity of ₹28 crore and reserves growing from ₹105 crore to ₹122 crore over two years, indicating retained earnings despite low profitability. Borrowings remain low and relatively flat at ₹50–51 crore, with no significant debt reduction or new financing disclosed. Total assets have increased modestly, suggesting capital deployment without aggressive expansion, consistent with a conservative capital allocation strategy focused on maintaining solvency rather than funding growth.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | +10 |
| Investing | -6 |
| Financing | -4 |
| Net Cash Flow | -0 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 44.8% | 39.1% | 37.7% | 37.7% |
| FII | 1.1% | 3.9% | 4.2% | 4.8% |
| DII | 0.0% | 0.0% | 1.6% | 1.6% |
| Public | 47.0% | 45.4% | 43.7% | 41.7% |
| # Shareholders | 14,897 | 14,063 | 14,188 | 13,478 |
Promoter holding has declined sharply from 44.8% in Q2 FY26 to 37.71% in Q1 FY27, while public shareholders have increased from 47.01% to 43.71% in Q4 FY26 and 41.66% in Q1 FY27, suggesting partial dilution or promoter selling. FII holdings have fluctuated between 1.13% and 4.8%, with a recent uptick to 4.8% in Q1 FY27, while DII holdings remain minimal and stable. The rising number of shareholders (13,478 to 14,897) indicates retail investor interest, but institutional accumulation remains limited and volatile.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.41 L Cr | 36.5 | 18.7% | — | 0.05 |
| DIVISLAB | 2.53 L Cr | 86.5 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.85 L Cr | 77.7 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.21 L Cr | 27.0 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.3 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.09 L Cr | 99.3 | 20.8% | — | 0.45 |
| DRREDDY | 1.02 L Cr | 31.6 | 10.1% | — | 0.17 |
| MANKIND | 1.01 L Cr | 49.3 | 13.9% | — | 0.38 |
| AUROPHARMA | 97,814 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,274 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1. Persistent low margins and volatility in revenue and profitability raise concerns about operational resilience, especially with no clear demand recovery signal. 2. The company’s reliance on regulatory compliance narratives without strategic growth communication suggests limited management confidence or visibility. 3. Declining promoter stake and lack of institutional accumulation beyond sporadic FII buying indicate weak investor conviction. 4. No disclosed capital expenditure plans or product pipeline updates increase uncertainty around future cash flow generation.
📋 Recent Filings
- Announcement2026-09-23Aarey Drugs & Pharmaceuticals announced that its insider trading window will close on October 1, 2026, ahead of the upcoming unaudited financial resul…
- 🔴 annual report2026-09-11Aarey Drugs & Pharmaceuticals disclosed that its integrated annual report for FY2025-26 is available online at http://www.aareydrugs.com/investors.htm…
- 🟡 Board Meeting2026-09-08Aarey Drugs & Pharmaceuticals announced a book closure for its 36th Annual General Meeting scheduled from 24 to 30 September 2026, during which the Re…
- 🟡 Board Meeting2026-09-08Aarey Drugs & Pharmaceuticals announced its 36th Annual General Meeting on September 30, 2026 at 3:00 PM via video conferencing, accompanied by the In…
- 🔴 annual report2026-09-08Aarey Drugs & Pharmaceuticals Ltd (AAREYDRUGS) filed its 2025-26 Annual Report on September 8, 2026, announcing the 36th AGM scheduled for September 3…
- 🟡 Board Meeting2026-09-05Aarey Drugs & Pharmaceuticals announced its board approved the draft annual report and scheduled the 36th Annual General Meeting for September 30, 202…
- 🟡 Board Meeting2026-08-14The board approved unaudited Q1 FY26 standalone financial results showing revenue of [amount not verified], profit before tax of [amount not verified]…
- Financial Results2026-06-26Aarey Drugs & Pharmaceuticals Limited announced that its trading window closes on July 1, 2026, for insiders and designated persons until 48 hours aft…
- 🟡 Board Meeting2026-05-30The board approved the audited standalone financial results for Q4 and FY2025-26 ending March 31, 2026, including an unmodified audit opinion, and con…
- share transfer2026-04-14Aarey Drugs & Pharmaceuticals announced it received a SEBI-mandated certificate from MUFG Intime India Private Limited, its share transfer agent, conf…
🧠 Analyst's Read
Aarey Drugs remains a low-visibility, compliance-focused pharmaceutical player with modest scale and inconsistent financial performance. Investors should monitor upcoming earnings calls and board discussions for any strategic clarity, particularly around demand trends, margin improvement initiatives, or capital allocation priorities, as current disclosures offer limited insight into sustainable growth drivers.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-29.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts when AAREYDRUGS files new disclosures
Track AAREYDRUGS filings, board meetings, and corporate actions. Free email alerts at 5 PM.
Track AAREYDRUGS — FreeFree account · 2 AI queries/day